| SBIO | |
|---|---|
| Fund Stats as of 06/22/2017 | |
| Symbol | SBIO |
| CUSIP | 00162Q 593 |
| ISIN | US00162Q5936 |
| Inception Date | 12/30/2014 |
| Dividends Paid | Annual |
| Fund Type | Exchange Traded Fund |
| Market Price | $28.10 |
| Last Trade Price | $28.13 |
| NAV | $28.10 |
| NAV Change | $0.14 |
| Total Net Assets | $115,199,531 |
| Total Market Value | $115,213,008 |
| Premium/Discount(%) | 0.00% |
| Difference ($) | $0.00 |
| Volume | 49,830 |
| Shares Outstanding | 4,100,000 |
| Expenses as of 03/31/2016 | |
| Management Fee | 0.50% |
| Other Expenses | 0.00% |
| Total Operating Expenses | 0.50% |
| Fund Resources | |
|---|---|
| Summary Prospectus | |
| Statement of Additional Information | |
| Quarterly Fact Sheet | |
| Quarterly Scorecard | |
| Statutory Prospectus | |
| Resource Library | |
The performance data quoted above represents past performance. Past performance is not a guarantee of future results. Investment return and value of the Fund shares will fluctuate so that an investor's shares, when sold, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Recent quarter end performance data.
The above frequency distribution chart presents information about the difference between the daily market price for shares of the Fund and the Fund's reported net asset value. The amount that the fund's market price is above the reported NAV is called the premium. The amount that the fund's market price is below the reported NAV is called the discount. The market price is determined using the midpoint between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00 pm Eastern time). The horizontal axis of the chart shows the premium or discount expressed in basis points. The vertical axis indicates the number of trading days in the period covered by the chart. Each bar in the chart shows the number of trading days in which the Fund traded within the premium/discount range indicated.
Menu
Market Price is based on the midpoint of the bid/ask spread at 4 p.m. ET and does not represent the returns an investor would receive if shares were traded at other times.
This fund may not be suitable for all investors. There are risks involved with investing in ETFs including the loss of money. The Fund is considered nondiversified and as a result may experience great volatility than a diversified fund. The Fund’s investments are concentrated in the pharmaceuticals and biotechnology industries, and underperformance in these areas will result in underperformance in the Fund. Investments in small and micro capitalization companies are more volatile than companies with larger market capitalizations.
Companies in the pharmaceuticals and biotechnology industry may be subject to extensive litigation based on product liability and similar claims. Legislation introduced or considered by certain governments on such industries or on the healthcare sector cannot be predicted.
Companies in the pharmaceuticals industry are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. The profitability of some companies in the pharmaceuticals industry may be dependent on a relatively limited number of products. In addition, their products can become obsolete due to industry innovation, changes in technologies or other market developments. Many new products in the pharmaceuticals industry are subject to government approvals, regulation and reimbursement rates. The process of obtaining government approvals may be long and costly. Many companies in the pharmaceuticals industry are heavily dependent on patents and intellectual property rights. The loss or impairment of these rights may adversely affect the profitability of these companies.
The development of new drugs generally has a high failure rate, and such failures may negatively impact the stock price of the company developing the failed drug. Biotechnology companies may have persistent losses during a new product’s transition from development to production. In order to fund operations, biotechnology companies may require financing from the capital markets, which may not always be available on satisfactory terms or at all.
Click here for terms and indexes used on this page. One cannot invest directly in an index.
Important Considerations
Investors should consider investment objectives, risks, charges and expenses carefully before investing. The prospectus contains this and other important information. For a prospectus for the above listed funds, please click here. Please read the prospectus carefully before investing. For additional information on the above listed funds, please click the respective link.
Insurance Products Shares of the Portfolios are offered only to participating insurance companies and their separate accounts to fund the benefits of Variable Contracts, and to qualified pension and retirement plans and registered and unregistered separate accounts.
Closed-End Funds do not continuously issue shares for sale as open-end mutual funds do. Since the initial public offering, the Funds now trade in the secondary market. Investors wishing to buy or sell shares need to place orders through an intermediary or broker. The share price of a closed-end fund is based on the market's value. The Fund's investment objective is fundamental and may not be changed without the vote of the Fund's shareholders.
USO, USL, DNO, UNG, UNL, UGA, UHN, BNO, USCI, CPER and USAG are not mutual funds or any other type of Investment Company within the meaning of the Investment Company Act of 1940, as amended, and are not subject to regulation thereunder.
Shares of Exchange Traded Funds (ETFs) are not individually redeemable and owners of the shares may acquire those shares from the ETF and tender those shares for redemption to the ETF in Creation Units only, see the ETF prospectus for additional information regarding Creation Units. Investors may purchase or sell ETF shares throughout the day through any brokerage account, which will result in typical brokerage commissions.
With the exception of the closed-end funds listed above, ALPS Distributors, Inc. and/or ALPS Portfolio Solutions Distributor, Inc., 1290 Broadway, Denver, CO 80203, is the distributor for the open-end mutual funds and exchange-traded funds/products on this website.
The Funds described on this website are offered to United States residents only. Information on this site should not be considered a solicitation to buy or an offer to sell a security any persons outside the United States.
ALPS Advisors, Inc., ALPS Distributors, Inc., ALPS Portfolio Solutions Distributor, Inc., and ALPS Fund Services, Inc. are subsidiaries of ALPS Holdings, Inc. ALPS Distributors, Inc. and ALPS Portfolio Solutions Distributor, Inc. are registered broker-dealers and FINRA Members.
© 2010-2017 - ALPS Advisors Inc. - All rights reserved.